Abstract Hypertension is the most common chronic condition seen by physicians in ambulatory care and a condition for which life-long medications are commonly prescribed. There is evidence for genetic factors influencing blood pressure variation in populations and response to medications. This review summarizes recent genetic discoveries that surround blood pressure, hypertension, and antihypertensive drug response from genome-wide association studies, while highlighting ancestry-specific findings and any potential implication for drug therapy targets. Genome-wide association studies have identified several novel loci for inter-individual variation of blood pressure and hypertension risk in the general population. Evidence from pharmacogenetic studies suggests that genes influence the blood pressure response to antihypertensive drugs, although results are somewhat inconsistent across studies. There is still much work that remains to be done to identify genes both for efficacy and adverse events of antihypertensive medications.
Introduction
Hypertension is the most common chronic condition seen by physicians in ambulatory care [1] and a condition for which life-long medications are commonly prescribed. In the USA, hypertension affects one-third of the adult population, has increased among children and adolescents, affecting disproportionally some ethnic/racial subgroups [2, 3] . From the clinical and public health perspective, the major long-term impact of hypertension is resultant end-organ damage to the kidneys, heart, vessels, and brain, leading to premature mortality, disability, and significantly increased economic and societal cost [4] [5] [6] . Evidence from clinical trials has shown that lowering blood pressure reduces the risk of stroke, coronary heart disease, and mortality [7] [8] [9] [10] [11] [12] , in addition to slowing the progression of chronic kidney disease [13] . African Americans are a subgroup who suffer a greater burden of hypertension and its complications, and are more likely to have uncontrolled hypertension [14] and to require multiple drugs for blood pressure (BP) control compared with other US racial/ethnic subgroups [15] . Genetic factors also contribute to hypertension and may interact with environmental exposures (including pharmacological agents) and social-lifestyle habits in contributing to disparities in hypertension prevalence and severity observed across diverse race/ethnic subgroups.
This review summarizes recent genetic discoveries that surround BP, hypertension, and antihypertensive drug response from studies of the general population and those from pharmacogenomic settings, while highlighting ancestry-specific findings and any potential implication for drug therapy targets. We focused on discovery efforts seeking (1) loci contributing to the inter-individual variation in BP and hypertension risk using large-scale genetic approaches, including genome-wide association studies (GWAS), applied to cohorts of individuals recruited from the general population, and (2) loci identified through GWAS of pharmacologic traits, including those related to clinical response to antihypertensive medications. The first approach is an unbiased scan of the entire genome aiming to provide insights into the genes contributing to the biology of BP regulation, to suggest targets for therapy and for population-level risk reduction. The second approach focuses specifically on identifying genetic variants influencing drug response, including drugs used for the treatment of hypertension, and/or genetic variants associated with side effects of drugs. Pharmacogenetics holds the promise of providing individualized clinical care, by identifying subgroups based on their response to commonly used drugs for hypertension and/or subgroups at higher risk for harmful side-effects of drugs and thus tailoring therapy to an individual's genetic makeup. Although both approaches have already identified numerous genes related to BP, hypertension, and antihypertensive drug response, the functional variants underlying most associations remain largely unknown and much work is still needed to translate the findings to the clinical care of patients.
Blood Pressure Loci Identified in Studies of the General Population
Common Variants Identified in GWAS and Admixture Models The heritability of BP is substantial (in the range of 30-55 %), suggesting a large number of contributing genetic variants, the vast majority of which are yet to be discovered [16•, 17] . Genetic analysis of Mendelian, i.e., extreme forms of hypertension and hypotension, has highlighted some pathways of BP regulation in humans and these findings comprise rare genetic variants with large impact in BP [17, 18] . However, identifying genes related to common variation in BP and essential hypertension has proven challenging. Hypertension-and its response to treatment-is a complex trait that is likely influenced by a large number of genetic variants, each with small effects, and possibly modulated by environmental factors including diet, lifestyle, and other exposures. Recent genetic discovery efforts for this class of genetic variation have focused on unbiased scans of the genome for associations with BP traits using data from individuals recruited from the general population, a proportion of them having essential hypertension. This GWAS approach examines the association of hundreds of thousands of genetic markers commonly seen in the population (single-nucleotide polymorphisms, SNPs), and relies on stringent statistical criteria for discovery of loci in order to account for multiple testing (typically p<5×10 -8 ).
Validation of genomic regions is further provided by replication of the associations in additional samples. Because genetic variants vary in allele frequency across race/ethnicity and the patterns of correlation among genetic markers also vary by ancestry and admixture, studies are performed within each ancestrally homogenous group separately.
The first two BP GWAS [19, 20] discovered 13 BP loci and were followed by a combined effort from the International Consortia of Blood Pressure (ICBP) [16•] reporting additional associations for a total of 28 loci for systolic and diastolic BP and/or hypertension. Subsequent studies reported over 55 loci for BP in GWAS of pulse pressure and mean arterial pressure [21] , GWAS using extremes of the BP distribution or hypertension [22, 23] , and in studies using gene-centric arrays, which provide a better genomic coverage for some loci [24] [25] [26] . The identified genetic variants from GWAS have small effects and explained only a small proportion of the trait variation. For example, 29 SNPs in the 28 loci identified in ICBP explained less than 1 % of the inter-individual variation in BP [16•] . However, findings from GWAS have already uncovered some biology and potential targets for drug therapy (discussed under "Genes, Pathways, and Potential Role for Pharmacogenetics").
The ICBP and several other recently published studies have studied mostly individuals of European ancestry [16•, 19, 20, 22-25, 27] . Studies of non-European ancestry including East Asians [28•, 29] and African ancestry [30, 31•] have contributed additional information to the genetic architecture of BP, though their sample sizes are limited. For example, a GWAS of BP in East Asians identified four novel BP loci, and evidence for an ethnic-specific variant at ALDH2 (aldehyde dehydrogenase 2). The ALDH2 variant was highly correlated with a known functional variant (rs671), which was previously associated with hypertension modulated by alcohol intake in East Asians [28•] .
Individuals of African ancestry have more genomic diversity and less linkage disequilibrium (correlations among SNPs) compared with European and Asian populations [32] . These genomic differences can be helpful in gene discovery and also in narrowing genomic regions within identified loci to identify functional variants for BP. Using admixture mapping approaches followed by association analyses, Zhu et al. [30] Identified the NPR3 (natriuretic peptide receptor 3) locus for systolic and diastolic BP in African Americans, subsequently shown to be associated with BP traits in individuals of European ancestry [16•] and East Asians [28•] . In a recent meta-analysis of 19 GWAS of African ancestry participants of the Continental Origins and Genetic Epidemiology Network Blood Pressure (COGENT-BP) consortium, three novel loci for BP (EVX1-HOXA, RSPO3, PLEKHG1) [31•] were identified, although the discovery sample (including 29,000 individuals) was half of the ICBP sample, thus highlighting the potential for differences according to ancestry. RSPO3 (R-spondin 3)-encoded protein activates the Wnt/beta-catenin signaling pathways, and the locus has been previously associated with blood urea nitrogen levels, a measure of kidney function [33] . There was also evidence for an additional novel variant at the previously reported locus SOX6. Of interest, genetic loci identified in individuals of African ancestry replicated across European and East Asian individuals in a trans-ethnic meta-analysis. Therefore, studies of nonEuropean ancestry are essential for trans-ethnic gene discovery, as common genetic variants may have broad effects across ancestries in the population.
Rare Variants Influencing BP Traits In addition to common genetic variants, recent studies have shown that low frequency variants (minor allele frequency between 0.5 and 5 %) [34] can have large effects and may explain some of the missing heritability of complex traits [35] . Importantly, rare variants constitute the vast majority of polymorphic sites in human populations [34] . Low-frequency and population-specific variants are not well captured by current GWAS genotyping platforms, particularly among non-European ancestry populations. Studies of low frequency variants using sequencing data and 1000 Genomes Project imputed data are ongoing, and examples of loci associations with BP traits have not yet been published. However, a candidate gene sequencing study identified rare variants in kidney solute transporters, all of which are targets for diuretics, which were associated with low BP in the Framingham Heart Study [36] . These included variants in the SLC12A3 (thiazide-sensitive Na-Cl cotransporter, the target of thiazide diuretics), SLC12A1 (Na-K-Cl cotransporter NKCC2, the target of loop diuretics furosemide and bumetanide) and KCNJ1 (K+ channel ROMK) genes [36] . Because rare variants tend to be population-specific [37] , future studies may provide evidence for ancestry-specific variants at low frequency influencing the genetic architecture of BP traits.
Genes, Pathways, and Potential Role for Pharmacogenetics
Most genomic regions identified in BP GWAS include genes of unknown function, but some loci include genes known or suspected to be involved in BP pathways and/or are targets of antihypertensive drugs (Table 1 ). The CYP17A1 (cytochrome P450 enzyme) protein is a key enzyme in the steroidogenic pathway that produces mineralocorticoids and glucocorticoids, and rare Mendelian mutations manifest by congenital adrenal hyperplasia and hypokalemic hypertension [38] . This locus has been identified in GWAS of both European and East Asian individuals [16•, 28•] . The ADM (adrenomedullin) protein is a hypotensive peptide found in human pheochromocytoma [39] , a disease manifested by paroxysmal hypertension and a cause of secondary hypertension [40] . ADRB1 encodes the β-1 adrenergic receptor, a guanine nucleotidebinding regulatory protein-coupled receptor target of β-adrenergic receptor blockers. SNPs nearby or within the gene have been associated with mean arterial pressure in GWAS [21] and a lower risk of essential hypertension [41] . Vasoactive peptides including natriuretic peptides and endothelin have a well-known role in BP control. Several genes in these pathways have been identified in GWAS of BP including NPPA/NPPB (precursors of atrial-and B-type natriuretic peptides), NPR3 (natriuretic peptide clearance receptor), and EDN3 (endothelin 3). Soluble guanylyl cyclase, the product of the GUCY1A3-GUCY1B3 genes, generates cyclic guanosine monophosphate (cGMP) under stimulation by nitric oxide, inducing vasodilation. NOS3 encodes nitric oxide synthase 3, which is responsible for the conversion of l-arginine to the vasodilator nitric oxide. Several calcium and potassium channel genes have been identified in GWAS of BP traits including ATP2B1, CACNB2 and KCNJ11, and their pharmacologic targets are shown in Table 1 . Genes related to the renin-angiotensin-aldosterone system identified in BP GWAS are ENPEP, which encodes a glytamyl aminopeptidase involved in the conversion of angiotensin II to angiotensin III, and AGT, which encodes angiotensinogen precursor, the target of renin conversion to angiotensin I. FURIN encodes a protease involved in the processing of protein precursors including the prorenin receptor. Except for AGT, the effect of polymorphisms in these genes in response to therapy has not been studied. AGT variants have been also shown to interact with a low-salt diet [42, 43] .
Kidney Genes, BP and Hypertension The role of the kidneys on BP homeostasis is well-defined through mechanisms related to salt reabsorption and volume control. BP GWAS identified two kidney solute transporters, SLC4A7 (electro-neutral sodium bicarbonate co-transporter) and SLC39A8 (solute carrier family 39 [zinc transporter], member 8), but their role in BP regulation remains unknown [16•] . SLC39A8 is the major transporter of cadmium into cells in humans, an environmental metal pollutant that has been associated with endothelial dysfunction, oxidative stress, and hypertension in populations [44] [45] [46] [47] .
UMOD (uromodulin) is highly expressed in the kidney's thick ascending limb and encodes the Tamm-Horsfall protein, the most abundant protein excreted in normal urine. In GWAS, variants in the promoter of UMOD (rs4293393, rs13333226) associated with lower BP and with a better kidney function [23, 48] . Transgenic mice with overexpression of uromodulin manifest salt-sensitive hypertension, aging-related kidney pathology, and activation of the thick ascending limb sodium cotransporter NKCC2, the target of loop diuretics [49] . Hypertensive individuals homozygous for UMOD at risk variant rs4293393 demonstrated a lowering of BP salt sensitivity response when treated with furosemide compared to other hypertensive individuals [49] . rs4293393 is common in all ethnic groups represented in HapMap and the 1000 Genomes Project, suggesting a potential role in hypertension across diverse ancestry groups.
Chronic kidney disease is usually accompanied by hypertension. A gene known to cause chronic kidney disease and secondary hypertension is APOL1 (apolipoprotein L, 1), recently reviewed in this journal [50] . Two APOL1 alleles, under positive selection in populations of African ancestry, confer substantial risk of focal segmental glomerulosclerosis, HIV-associated nephropathy and hypertensive-attributed nephropathy [51] [52] [53] . This is also an example of ancestry-specific variants common in the population that present risk for hypertension.
GWAS Findings and Drug
Repositioning Sauseau et al. recently examined the utility of GWAS data in identifying drug targets or alternative clinical indications for existing drugs [54] . Using a set of 991 GWAS genes identified from publications listed in the genome catalog up to 2011, they found that 21 % of the genes were amenable to pharmacological modulation using small molecules and 47 % using biopharmaceuticals, which was a significantly higher [27] . Genetic variants within 60 kb of 30 drug target genes were selected and tested for associations with BP and hypertension traits in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (n = 29,136). Replication was performed in over 57,000 European ancestry individuals. The study found associations of a nonsynonymous variant in the ADRB1 gene with systolic and diastolic BP, and hypertension, and a variant in AGT was associated with systolic BP and hypertension [27] .
Loci Identified in Pharmacogenetic Studies
Pharmacologic exposures can modify the effects of genes influencing BP and contribute to antihypertensive response and overall cardiovascular risk. Genetic factors can influence the response to pharmacologic agents and/or can guide treatment strategies such as avoiding side-effects and other harmful complications. Despite the promise of pharmacogenomics in the treatment of hypertensive patients, their use is still limited in clinical care. Given the complex regulatory mechanisms for BP, alternative strategies for the investigation of BP genes may prove informative for gene finding, for example, BP responses to pharmacologic interventions [55] . Recent GWAS for antihypertensive pharmacogenetics have identified NEDD4L (neural precursor cell expressed, developmentally downregulated 4-like) variants that are associated with antihypertensive response to diuretics [56] [57] [58] 66] , as well as PRKCA variants influencing BP response to thiazide diuretics [59•] (discussed below). The pharmacogenetics of antihypertensive treatment has been recently summarized [60, 61] . Evidence from studies suggests that genetics influence the BP response to antihypertensive drugs, although results are somewhat inconsistent across studies. Comparison of findings across studies is complicated by differences in study design, methods for assessing BP, pharmacologic exposures (including dose and duration), and small sample size. Pharmacogenetic studies of BP response and antihypertensive drug side effects can be found in the International Consortium for Antihypertensive Pharmacogenetic Studies (ICAPS) at www.pharmgkb.org/page/icaps. These studies include observational studies and clinical trials of antihypertensive drugs, and used candidate gene and GWAS genetic approaches. Below, we focus on findings from GWAS.
GWAS Studies of BP Drug Response
Two GWAS of BP drug response were recently published [59•, 62•] . These studies used data from randomized clinical trials. Gong et al. studied the association of SNPs in 37 BP GWAS loci (Illumina 50 K cardiovascular or Omni 1 M GWAS arrays) with response to atenolol and thiazide diuretics in 461 European and 298 African-ancestry hypertensive participants of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, a multicenter, randomized clinical trial of hydrochlorothiazide (HCTZ) versus atenolol [62•] . Although there was no genome-wide significant finding when corrected for multiple testing, a genetic risk score based on nominally significant associations in the array-wide analysis was significantly associated with response to atenolol and thiazides in individuals of European ancestry. Turner et al. studied the association of common variants influencing antihypertensive response to HCTZ in 424 hypertensive European Americans from the PEAR study and the Genetic Epidemiology of Responses to Antihypertensive (GERA) study [59•] . Among~1.1 million genetic markers tested, an SNP in PRKCA (rs16960228) was associated with greater systolic and diastolic BP response among carriers of the allele A, reaching genome-wide significance in a combined metaanalysis of discovery and additional replication samples. An SNP nearby GNAS-EDN3 (rs2273359), although replicated in independent samples, did not reach the genome-wide threshold for significance for BP response to HCTZ.
He et al. performed a GWAS of BP in response to dietary intervention and cold pressor test in 1,881 Han Chinese participants from the GenSalt study [63] . The GenSalt study included a 7-day low-sodium (51.3 mmol/d), a 7-day high-sodium (307.8 mmol/d), and a 7-day high-sodium plus potassium supplementation (60 mmol/d) diet intervention in addition to BP cold pressor test response. They identified eight novel loci that were associated with one or more traits and replicated in an additional sample of 698 Han Chinese individuals. These included SNPs in or near PRMT6, CDCA7, and PIBF1, which were associated with response to low-salt diet; IRAK1BP1 associated with high-sodium intervention; CDCA7, ARL4C, IRAK1BP1, and SALL1, associated with potassium supplementation; and TRPM8 and FBXL13 associated with cold pressor test response. In five of these loci, the SNPs were low-frequency markers (MAF 0.01 to 0.05). The effect sizes were higher than the ones seen in GWAS of BP, suggesting stronger genetic effects to response to interventions. Finally, there was a strong dose-response relationship between the cumulative allele count and the development of hypertension at follow-up.
GWAS Studies of Adverse Response to Antihypertensive Drugs
GWAS studies of adverse response to antihypertensive drugs have also been recently published. Del-Aguilla et al. studied the association of genetic markers with change in fasting plasma glucose and triglycerides in response to HCTZ using data from the PEAR and GERA studies [64] . They identified two genome-wide significant variants (rs12279250 and rs4319515) in the NELL1 gene associated with increased fasting triglycerides in African Americans. Each at-risk variant allele was associated with a large effect of approximately 28 mg/dl increase in plasma triglyceride levels. Using 33 SNPs previously associated with fasting glucose in white individuals, Gong et al. studied their association with druginduced glucose changes in the PEAR study [65] . An SNP in the 5' of the PROX1 gene (rs340874) was significantly associated with atenolol-induced glucose change, with a 2.39 mg/ dl increase in serum glucose per each copy of the C-allele. A GWAS of atenolol-induced HDL-C changes in the PEAR study was not significant [66] , although 13 regions showed consistent associations among whites and African Americans. These included seven loci previously related to lipid pathways or metabolic traits including GALNT2, FTO, ABCB1, LRP5, STARD3NL, ESR1, and LIPC. A study of angiotensinconverting enzyme inhibitor-associated angioedema (175 cases and 489 controls) failed to identify genome-wide significant SNPs associated with this complication [67] . In the INternational VErapamil SR Trandolapril Study (INVEST), a prospective, randomized study comparing two pharmacotherapy strategies to control hypertension in ambulatory patients with coronary artery disease, TCF7L2 polymorphisms were associated with HCTZ-induced diabetes [68] .
Taken together, although GWAS published studies are still limited, their findings suggest genetic effects for common variants in drug-induced side-effects. Nonetheless, GWAS discovery studies of BP drug response are limited by small sample size and are likely too underpowered to identify novel loci.
Ancestry and Choice of Hypertension Medications
A recent report from the authors originally convened as the 8th Joint National Committee [69] recommends different first-line for antihypertensive drugs in African-American compared to non-African-American hypertensive individuals (a calcium channel blocker or thiazide-type diuretics). Based on evidence from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trials [70] , in which black individuals taking a thiazide diuretic showed better stroke, heart failure, and combined cardiovascular outcomes compared to those taking an ACE inhibitor. For the non-AfricanAmerican population, the new report recommends an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, a calcium channel blocker or thiazide-type diuretic as first-line therapy. African Americans have greater increases in BP in response to sodium intake, i.e., salt sensitivity [71, 72] . A recent study by Tu et al. showed that increases in BP in African-American children and adults were associated with increased plasma aldosterone concentration and reduction in plasma renin activity [73] . This relationship was not seen in white individuals. African-American individuals also had higher BP response to an intervention using the synthetic mineralocorticoid 9-α-fludrocortisone, suggesting aldosterone sensitivity as a mechanism of hypertension [73] . It is likely that there is an underlying genetic component that explains the racial/ ethnic differences in response to therapy seen in clinical trials, although findings are yet to be published.
Future Research and Clinical Perspectives
While some progress has occurred recently in the search for genes contributing to the response to antihypertensive therapy, both in terms of efficacy and adverse events, there is much work that remains to be done. A challenge for researchers in the field is replication of significant findings in a different study population. Not only are trials expensive to conduct, there are few antihypertensive trials that are active and collecting DNA. Another challenge is the need to replicate findings with the same drug or even the same drug class. The recent formation of the ICAPS (International Consortium for Antihypertensive Pharmacogenetic Studies) is a step forward towards replication. A second major challenge is the lack of trans-ethnic GWAS to identify common targets across ancestries. Finally, there is currently an absence of validated genome-based measures with sufficient clinical utility to be implemented in clinical practice.
Conclusions
GWAS have identified over 55 loci associated with blood pressure and hypertension traits. These loci harbor genes that are either established or potential targets for antihypertensive drugs. Studies of non-European ancestry are important to leverage trans-ethnic gene discovery, and to narrow down genomic regions where putative genetic variants (common or rare) are located. Although there is evidence for genes influencing the blood pressure response to antihypertensive drugs, few pharmacogenetic GWAS of antihypertensive drugs have been reported. Challenges for these studies are their small sample sizes, the lack of ancestry diversity, and difficulties in finding replication samples.
